Femoral Access and Delivery of Continuous Renal Replacement Therapy Dose
Rinaldo Bellomo, Johan Martensson, Serigne Lo, Kirsi-Maija Kaukonen, Alan Cass, Martin Gallagher
Blood Purification | KARGER | Published : 2016
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by Health Research Council (HRC) of New Zealand
This study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (grant 352550) and Health Research Council (HRC) of New Zealand (grant 06-357). The study sponsors had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.Professor A. Cass received funding from the Australian National Health and Medical Research Council and grant support from Roche and Gambro. Professor R. Bellomo received consulting fees as an advisor for Gambro; and consulted for Gambro, Biosite, Abbott and Philipps. Dr. M. Gallagher received honoraria/speaking fees from Roche. Dr. J. Martensson received travel support to present research results at scientific meetings from Gambro and funding from Karolinska Institutet. The remaining authors have not disclosed any potential conflicts of interest.The George Institute has received research funding from Servier, Novartis, Eisai, Merck, Sharp & Dohme, Pfizer Australia, Fresenius Kabi Deutschland GmbH and Sanofi Aventis.